Intravenous administration of halogenated inhaled anesthetics-research tool or real application?;L'administration intraveineuse d'agents anesthésiques halogénés inhalés : Un outil de recherche ou des applications concretes?

Canadian Journal of Anesthesia

Volumn 56, Issue 2, 2009, Pages 91-95

  Raphael, Jacob ^a   Lynch, Carl ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INHALATION ANESTHETIC AGENT; INTRAVENOUS ANESTHETIC AGENT;

ANIMAL; CHEMISTRY; EDITORIAL; HALOGENATION; HEART INFARCTION; HUMAN; POSTOPERATIVE COMPLICATION; REPERFUSION INJURY; SOLUBILITY;

ANESTHETICS, INHALATION; ANESTHETICS, INTRAVENOUS; ANIMALS; HALOGENATION; HUMANS; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION INJURY; POSTOPERATIVE COMPLICATIONS; SOLUBILITY;

EID: 64849096646     PISSN: 0832610X     EISSN: 14968975     Source Type: Journal    
DOI: 10.1007/s12630-008-9026-1     Document Type: Review

References (16)

1. Mangano DT, Layug EL, Wallace A, Tateo I. Effect of atenolol on mortality and cardiovascular morbidity after noncardiac surgery. Multicenter Study of Perioperative Ischemia Research Group. N Engl J Med 1996; 335: 1713-20.
2. Tanaka K, Ludwig LM, Kersten JR, Pagel PS, Warltier DC. Mechanisms of cardioprotection by volatile anesthetics. Anesthesiology 2004; 100: 707-21.
3. Hu ZY, Luo NF, Liu J. The protective effects of emulsified isoflurane on myocardial ischemia and reperfusion injury in rats. Can J Anesth 2009; 56.
4. Lucchinetti E, Schaub MC, Zaugg M. Emulsified intravenous versus evaporated inhaled isoflurane for heart protection: Old wine in a new bottle or true innovation? Anesth Analg 2008; 106: 1346-9.
5. Liu J, Yang X, Ma H, Yang Z, Zhang W. Comparison of MAC between intravenous injected isoflurane lipid emulsion and inhaled isoflurane in dogs. Anesthesiology 2004; 101: A127 (abstract).
6. Chiari PC, Pagel PS, Tanaka K, et al. Intravenous emulsified halogenated anesthetics produce acute and delayed preconditioning against myocardial infarction in rabbits. Anesthesiology 2004; 101: 1160-6.
7. Zhang WS, Ma HX, Yang XL, Luo NF, Liu J. Anesthetic potency and safety of isoflurane injection in rats and dogs. Anesthesiology 2005; 103: A745 (abstract).
8. Lucchinetti E, Ambrosio S, Aguirre J, et al. Sevoflurane inhalation at sedative concentrations provides endothelial protection against ischemia-reperfusion injury in humans. Anesthesiology 2007; 106: 262-8.
9. Ferezou J, Bach AC. Structure and metabolic fate of triacylglycerol-and phospholipid-rich particles of commercial parenteral fat emulsions. Nutrition 1999; 15: 44-50.
10. Kawakami S, Yamashita F, Hashida M. Disposition characteristics of emulsions and incorporated drugs after systemic or local injection. Adv Drug Deliv Rev 2000; 45: 77-88.
11. Suzuki Y, Masumitsu Y, Okudaira K, Hayashi M. The effects of emulsifying agents on disposition of lipid-soluble drugs included in fat emulsion. Drug Metab Pharmacokinet 2004; 19: 62-7.
12. Patel HH, Tsutsumi YM, Head BP, et al. Mechanisms of cardiac protection from ischemia/reperfusion injury: A role for caveolae and caveolin-1. FASEB J 2007; 21: 1565-74.
13. Krafft MP. Fluorocarbons and fluorinated amphiphiles in drug delivery and biomedical research. Adv Drug Deliv Rev 2001; 47: 209-28.
14. Riess JG. Fluorinated vesicles. J Drug Target 1994; 2: 455-68.
15. Fast JP, Perkins MG, Pearce RA, Mecozzi S. Fluoropolymerbased emulsions for the intravenous delivery of sevoflurane. Anesthesiology 2008; 109: 651-6.
16. Cuignet OY, Baele PM, Van Obbergh LJ. A second-generation blood substitute (perflubron emulsion) increases the blood solubility of modern volatile anesthetics in vitro. Anesth Analg 2002; 95: 368-72.